Featured Research

from universities, journals, and other organizations

Patients with long-term conditions need greater support to return to work

Date:
March 16, 2010
Source:
Society for Endocrinology
Summary:
A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment. The group found that under half of patients with chronic endocrine conditions returned to work.

A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment. The research is being presented at the annual Society for Endocrinology BES meeting in Manchester. Led by Prof John Wass of the Churchill Hospital, Oxford, the group found that under half of patients with chronic endocrine conditions returned to work.

This study is the first to show the effect of long-term endocrine conditions on employment status, and highlights the need for increased medical and social support for patients to return to work.

Endocrine conditions result in life-long imbalances in the body's hormones, however, symptoms can be stabilised with medication and patients can enjoy a healthy, normal life. However, patients suffering from chronic conditions may be at increased risk of long term unemployment, a known contributor to poorer health and increased health inequality. Improving return to work among this group of patients may contribute to improvements in their health and quality of life.

Prof John Wass, Dr Barbara Alberts and Dr Emily Parker examined unemployment and return to work rates amongst people with a variety of long-term endocrine conditions; Addison's disease, Cushing's disease, craniopharyngioma and Klinefelter's syndrome. In a group of 130 patients, the study found a high rate of unemployment (40.8% vs 27.5% for the UK population). 60.8% reported a period of unemployment which was related to their disease, and only 40% of 130 patients had entered or re-entered work following a period of unemployment.

Researcher Prof John Wass, Consultant Endocrinologist, Oxford Radcliffe Hospitals NHS Trust said: "Long term unemployment is a significant problem for people with chronic diseases. More people should consider returning to work following diagnosis and more doctors need to encourage and support their patients in this. Whilst a return to work may not be suitable for all patients, it can significantly improve their wellbeing and quality of life. As a country, we need to provide more support services to allow people with long-term conditions to re-enter the workplace, at a rate that is feasible for them."


Story Source:

The above story is based on materials provided by Society for Endocrinology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Barbara Alberts, Emily Parker & John Wass. Unemployment and return to work after the diagnosis of a chronic endocrine condition. Endocrine Abstracts, (2010) 21 P116

Cite This Page:

Society for Endocrinology. "Patients with long-term conditions need greater support to return to work." ScienceDaily. ScienceDaily, 16 March 2010. <www.sciencedaily.com/releases/2010/03/100316235813.htm>.
Society for Endocrinology. (2010, March 16). Patients with long-term conditions need greater support to return to work. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/03/100316235813.htm
Society for Endocrinology. "Patients with long-term conditions need greater support to return to work." ScienceDaily. www.sciencedaily.com/releases/2010/03/100316235813.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins